Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma
Open Access
- 21 October 2013
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 110 (45), 18226-18231
- https://doi.org/10.1073/pnas.1317577110
Abstract
Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in vivo. The energy-sensing AMP-activated protein kinase (AMPK) is known to be a major cellular target of biguanides. Based on our discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) signaling pathways, we investigated the antitumor effects of combining phenformin with a BRAF inhibitor PLX4720 on the proliferation of BRAF-mutated melanoma cells in vitro and on BRAF-driven tumor growth in vivo. Cotreatment of BRAF-mutated melanoma cell lines with phenformin and PLX4720 resulted in synergistic inhibition of cell viability, compared with the effects of the single agent alone. Moreover, treatment with phenformin significantly delayed the development of resistance to PLX4720 in cultured melanoma cells. Biochemical analyses showed that phenformin and PLX4720 exerted cooperative effects on inhibiting mTOR signaling and inducing apoptosis. Noticeably, phenformin selectively targeted subpopulations of cells expressing JARID1B, a marker for slow cycling melanoma cells, whereas PLX4720 selectively targeted JARID1B-negative cells. Finally, in contrast to their use as single agents, the combination of phenformin and PLX4720 induced tumor regression in both nude mice bearing melanoma xenografts and in a genetically engineered BRAFV600E/PTENnull-driven mouse model of melanoma. These results strongly suggest that significant therapeutic advantage may be achieved by combining AMPK activators such as phenformin with BRAF inhbitors for the treatment of melanoma.Keywords
This publication has 30 references indexed in Scilit:
- Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growthProceedings of the National Academy of Sciences of the United States of America, 2012
- Investigating Metformin for Cancer Prevention and Treatment: The End of the BeginningCancer Discovery, 2012
- Melanoma: from mutations to medicineGenes & Development, 2012
- From genes to drugs: targeted strategies for melanomaNature Reviews Cancer, 2012
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsThe New England Journal of Medicine, 2012
- Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanomaBioscience Reports, 2011
- Resistance to BRAF Inhibition in MelanomasThe New England Journal of Medicine, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor GrowthCell, 2010
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009